Polymorphisms in the IL-28B region are a strong predictor of sustained virologic response (SVR) in individual studies of HCV genotype 1 patients receiving peginterferon (pegIFN) and ribavirin.
SUMMARY Background
Polymorphisms in the IL-28B region are a strong predictor of sustained virologic response (SVR) in individual studies of HCV genotype 1 patients receiving peginterferon (pegIFN) and ribavirin.
Aim
To obtain a pooled odds ratio (OR) of SVR in patients of varying race with the favourable IL-28B genotype compared to those with the unfavourable genotype.
Methods
A literature search was conducted using online databases and a review of conference abstracts. A random effects meta-analysis was performed and study heterogeneity and publication bias were assessed.
Results
There were 21 individual studies of HCV genotype 1 patients of varying ethnicity treated with pegIFN and ribavirin. The pooled prevalence of the favourable IL-28B genotype varied by race (73% vs. 41% vs. 13% in 2612 Asians, 3110 Caucasians and 452 African-Americans, respectively, P < 0.001). However, the strength of association of the IL-28B genotype with SVR was similar in all three racial groups (Caucasians: odds ratio (OR) 3.88, 2.75-5.49, African-Americans: OR 4.63, 2.52-8.50 and Asians OR 5.66, 3.99-8.02, all P < 0.001). The IL-28B genotype was also associated with SVR in 263 HIV/HCV co-infected Caucasians (OR 5.49, 3.02-9.96, P < 0.001). Study quality score and anti-viral treatment regimen did not impact the strength of the association in patient subgroups nor in the pooled population.
Conclusions IL-28B genotype is significantly associated with SVR in HCV genotype 1 patients of varying race, as well as in HIV co-infected patients, receiving pegIFN and ribavirin. IL-28B testing in conjunction with other pre-treatment parameters may prove useful in counselling HCV patients. 
INTRODUCTION
Long-term sequelae of untreated chronic hepatitis C virus (HCV) infection include the development of progressive hepatic necroinflammation and fibrosis which can lead to life-threatening decompensated cirrhosis and hepatocellular carcinoma (HCC). 1 Nearly 50% of HCV patients will achieve a sustained virologic response (SVR) after treatment with peginterferon (pegIFN) and ribavirin for weeks that is associated with improved long-term clinical outcomes including survival compared with nonresponders. [2] [3] [4] [5] However, the majority of HCV patients in western countries are infected with HCV genotype 1, wherein the observed SVR rate is lower (40%) after 48 weeks of full dose pegIFN and ribavirin treatment. 4 As interferon therapy is associated with frequent and potentially serious side effects, it is important that clinicians be able to make accurate predictions regarding the likelihood of an SVR for individual patients with HCV genotype 1 infection. Clinical features associated with a lower likelihood of achieving SVR can be grouped into host, viral and treatment related factors. [3] [4] [5] [6] [7] [8] [9] Host factors associated with a poorer response include increasing patient age, male gender, higher body mass index (BMI), non-Caucasian race and greater degrees of hepatic steatosis and fibrosis on biopsy, whereas viral factors include HCV genotype 1/4 and a higher baseline viral load. In addition, the rate of decline in viral load at week 4 (i.e. rapid virologic response or RVR) and week 12 (i.e. early virologic response or EVR) provides additional prognostic value. 3, 6 A single nucleotide polymorphism (SNP) upstream of the interleukin 28B (IL-28B) gene on chromosome 19 was recently shown to be strongly associated with SVR in previously untreated HCV genotype 1 patients. 7 The identified polymorphism in this gene, which encodes for interferon-k-3, is associated with hepatic responsiveness to exogenously administered interferon as well as the rate of hepatocyte death. [8] [9] [10] In a cohort of treatment naïve HCV genotype 1 patients, the IL-28B SNP, rs12979860, was associated with a nearly two-fold higher SVR rate among patients with the favourable CC genotype compared to those with the CT or TT genotypes.
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The IL-28B polymorphism may also explain at least half of the difference in SVR rates observed in Caucasians and African-Americans who received the same treatment with comparable adherence. 7, 11 
Study selection criteria
Studies were selected based on the following inclusion criteria: (i) published studies of IL-28B genotyping in adults with chronic HCV genotype 1 infection; (ii) treatment with pegIFN and ribavirin and (iii) reported outcome of SVR. The following exclusion criteria were also used: (i) use of direct acting anti-viral agents (DAAs); (ii) treatment of patients who had undergone liver transplantation and (iii) use of IL-28B SNPs other than rs12979860 or rs8099917. All published studies regardless of the number of patients reported were included. After reviewing the titles and abstracts of all citations identified in the literature search, two investigators (AS, RF) independently applied the selection criteria and extracted data. Any disagreements were resolved by consensus, and agreement between investigators for selection of studies for this meta-analysis was greater than 95%.
Data extraction
Eligible studies were reviewed in a duplicate but independent manner by two investigators (AS, RF). For each study, the investigators collected the following data: Any discrepancies in data extraction were resolved by discussion among the investigators.
IL-28B testing
The two IL-28B SNPs reported in the individual studies were rs12979860 and rs8099917 which are in linkage disequilibrium with each other. The favourable genotype for rs12979860 is CC, whereas the unfavourable genotypes are CT and TT. The favourable genotype for rs8099917 is TT, whereas the unfavourable genotypes are TG and GG. Data from studies using both SNPs were initially merged as they are highly concordant in almost all East Asians and the majority of Caucasians. However, separate sensitivity analyses were conducted after excluding Caucasian studies using rs8099917 as the two SNPs do not reliably provide comparable results in this population. 13 When individual studies reported data for both SNPs, only the most robustly studied SNP for each race was chosen (i.e. rs8099917 for Asians and rs12979860 for non-Asians).
Primary outcome
The primary outcome for this meta-analysis was achievement of SVR after pegIFN and ribavirin treatment, which was defined as undetectable serum HCV RNA by polymerase chain reaction testing 24 weeks after treatment.
Secondary outcome
A secondary outcome for this meta-analysis was achievement of RVR with pegIFN and ribavirin treatment. RVR was defined as an undetectable serum HCV RNA at week 4 of treatment. An additional secondary outcome included crude pooled rates of the IL-28B genotype by race.
Quality assessment
A study quality assessment scale was created based on previously validated tools designed for diagnostic accuracy studies. [14] [15] [16] This eight-item scoring system involved questions about sample purity (based on inclusion of only treatment naïve and HCV genotype 1 patients), reporting of other known pre-treatment host factors associated with SVR and use of well-established HCV treatment algorithms with validated stopping rules. A score ! 6 was defined as high quality and a score <6 as low quality.
Statistical analysis
A pooled odds ratio (OR) of SVR based on the favourable IL-28B genotype was the estimate of effect, and was determined using the DerSimonian and Laird method for a random effects method. Study heterogeneity was assessed by the I 2 test, where an I 2 >50% is suggestive of substantial heterogeneity. Publication bias was assessed using the Harbord and Peters tests. Influence analysis was performed by removing one study at a time from the model to see if there was undue influence by a single study. All statistics were computed using STATA 11.0 (StataCorp LP, College Station, TX, USA). The data from the included studies were analysed separately by patient race. In addition, because the recommended dose of ribavirin is lower and the anticipated SVR rate is also lower in HIV co-infected patients compared with non-HIV patients, the HIV co-infection studies were analysed separately. Sensitivity and subgroup analyses were performed based on IL-28B SNP, treatment algorithm, treatment experience and overall study quality score. Specific comparisons were made using meta-regression.
RESULTS
Of the 180 published studies on IL-28B polymorphisms in HCV patients, 130 were eliminated due to the lack of reporting on virologic outcomes in treated patients. Among the 50 remaining studies, two involved the use of protease inhibitors with pegIFN and ribavirin, whereas three included liver transplant recipients. Of the 25 studies of HCV genotype 1 patients, four were reported in duplicate leaving a total of 21 analysable studies (Figure 1 ). Studies published only as abstracts were not included as they did not reliably provide extractable data for SVR stratified by IL-28B genotype.
Caucasians with HCV genotype 1 SVR outcome. There were nine studies of Caucasian patients with HCV genotype 1 who did not have HIV co-infection (Table 1) Figure  S1 ). Heterogeneity between studies was low (I 2 = 26%).
The OR of SVR in these same five studies was 4.40 (95% CI: 3.17-6.10, P < 0.001).
African-Americans with HCV genotype 1 SVR outcome. There were three studies of AfricanAmerican patients with HCV genotype 1 infection, and they all utilised full dose pegIFN and ribavirin treatment for 48 weeks (Table 1) . 11, 17, 25 These studies all reported data for the rs12979860 SNP. The favourable IL-28B genotype CC was present in only 13% of these 452 patients, which is significantly lower than that seen in the Caucasians and Asians (Figure 2 ). The SVR rate was 46% among CC patients compared to 19% among patients with the unfavourable IL-28B genotype with a pooled OR of 4.63 (95% CI: 2.52-8.50, P < 0.001) (Figure 3 ) and low study heterogeneity (I 2 = 0%). Week 4 RVR data were only reported in one study.
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Asians with HCV genotype 1 SVR outcome. There were eight studies of Asian patients with HCV genotype 1 treated with pegIFN and ribavirin ( Table 1) . [26] [27] [28] [29] [30] [31] [32] [33] These studies all used the rs8099917 SNP which is in strong linkage disequilibrium with rs12979860 in East Asians. 13, 29 The 73% prevalence of the favourable IL-28B genotype (TT) among the 2612 patients was significantly higher than the prevalence in both the Caucasians (P < 0.001) and African-Americans (P < 0.001) (Figure 2 ).
The pooled SVR rate was 58% in patients with the TT genotype compared to only 20% in patients with the unfavourable IL-28B genotype with a pooled OR of 5.66 Demographic data may be from all patients in the study population, including some who did not undergo IL-28B genotyping.
* Not all patients in each study underwent liver biopsy. In most studies, advanced fibrosis defined as Ishak score ! 4, METAVIR score ! 3. † Some patients treated with either standard IFN + RBV or standard IFN alone. ‡ Study does not clearly state whether all patients were treatment naïve. § Some patients were not treatment naïve. ¶ Defined advanced fibrosis as Ishak score ! 2.
** Used Scheuer scoring system for liver fibrosis. † † Used Ludwig and Batts scoring system for liver fibrosis.
(95% CI: 3.99-8.02, P < 0.001) (Figure 3 ). There was moderate heterogeneity among studies (I 2 = 56%).
Removing the two studies that clearly included previously treated nonresponders 28, 30 resulted in a pooled OR of SVR in the TT genotype of 5.06 (95% CI: 3.77-6.79, P < 0.001) with lower heterogeneity (I 2 = 32%). A subgroup analysis of the six high quality compared to the two low quality studies demonstrated similar OR (5.63 vs. 5.81, P = 0.98). Furthermore, the five studies that used full dose pegIFN and ribavirin for 48 weeks had a similar OR for SVR compared to the three studies that used alternative dosing and duration (6.14 vs. 4.87, P = 0.57).
RVR outcome. RVR data were reported in only two of the Asian studies. 27, 31 The favourable IL-28B genotype (TT) was present in 74% of the 722 pooled patients. The RVR rate was 25% in the TT patients as compared to 6% in the unfavourable IL-28B genotype patients, with a pooled OR of 4.07 (95% CI: 2.13-7.75, P < 0.001) (supplementary Figure S2 ).
HIV co-infected Caucasians with HCV genotype 1 SVR outcome. There were three studies of HIV (+) coinfected Caucasian patients with HCV genotype 1 treated with pegIFN and ribavirin (Table 1) . [34] [35] [36] The favourable IL-28B genotype of CC was present in 46% of the 263 pooled patients, which was not significantly different from the Caucasian HCV patients without HIV co-infection (46% vs. 41%, P = 0.17) (Figure 2) . Overall, 54% of the HIV (+) patients with the CC genotype achieved SVR compared to 20% of patients with the unfavourable IL-28B genotype with a pooled OR of 5.49 (95% CI: 3.02-9.96, P < 0.001) (Figure 4 ) and there was low heterogeneity (I 2 = 0%). However, none of these studies reported week 4 viral kinetics.
Pooled analysis
As the impact of IL-28B genotype on SVR appeared similar in all four of the analysed groups ( Figures 3 and 4) , the data were pooled to increase the ability to determine the impact of other study features. After combining all 21 studies with a total of 6437 patients, the pooled OR of SVR for patients with the favourable IL-28B genotype remained significant at 4.68 (95% CI: 3.75-5.83, P < 0.001). There was moderate heterogeneity between studies (I 2 = 58%), which was minimised with removal Table S1 ). There was no evidence of publication bias based on the Harbord and Peters tests (P = 0.29 and P = 0.48 respectively).
DISCUSSION
This meta-analysis clearly demonstrates that the prevalence of the favourable IL-28B polymorphism (CC) is significantly influenced by subject race (Figure 2 ). In addition, a consistent and significantly higher SVR rate was noted in all of the patient groups analysed among the patients with the favourable IL-28B genotype (Figure 3 ). These observations indicate that the IL-28B region plays a fundamental role in the response of all HCV genotype 1 patients to interferon-based therapy. In addition, the similar OR of the favourable IL-28B genotype in predicting SVR in the HIV co-infected Caucasian genotype by ethnic group. The prevalence of the favourable IL-28B (rs12979860 CC or rs8099917 TT) was significantly higher in Caucasian vs. AfricanAmerican patients (41% vs. 13%, P < 0.001) and in Asians vs. Caucasian (73% vs. 41%, P < 0.001) patients without HIV co-infection. In contrast, the prevalence was similar in the Caucasian HCV patients with and without HIV co-infection (46% vs. 41%, P = 0.13). patients when compared with the HIV (À) Caucasian patients (5.49 vs. 3.88, P = 0.36) (Figures 3 and 4) indicates that this factor is equally important in immunosuppressed individuals who generally have a lower likelihood of SVR due to higher baseline levels of HCV RNA and more severe liver disease. [37] [38] [39] The SVR rate with a 48-week course of pegIFN and ribavirin treatment has traditionally been highest in Asian populations, lowest in African-Americans and intermediate in Caucasians. 6, 40 In our analysis, the pooled SVR rates were substantially lower in AfricanAmericans (22%) as compared with the other two groups, but similar in Asians (48%) and Caucasians (49%). We noted a particularly lower than expected pooled SVR in the Asian IL-28B favourable patients (58%) compared with the unfavourable Asian IL-28B genotypes (20%) ( Table 1) . This finding may, in part, be related to the inclusion of Asian patients who had previously failed pegIFN and ribavirin therapy in up to six of the studies. Although we were unable to determine the exact proportion of previously treated patients, one would anticipate that this may be a biased population towards general nonresponders who may have a lower than expected response to treatment as was noted in our subgroup analysis of Caucasian patients. In addition, the use of shorter durations of combination therapy in three of the Asian studies, lower doses of ribavirin in five of the studies and a higher overall proportion of patients with advanced liver fibrosis may have played a role (Table 1) .
Multivariate regression analyses conducted in several of the individual studies confirmed that IL-28B genotype remains a significant pre-treatment predictor of SVR even after controlling for other well-known host and viral factors. 11, 17, 21, 25-27, 29, 31, 33-36 However, because these data were not provided in an analysable format, we were unable to combine the IL-28B data with other clinical variables to develop a robust mathematical model from the pooled results. How to use IL-28B data with other pre-treatment predictors to accurately estimate an individual patient's chance of response to therapy remains a clinically important, but unresolved issue. [41] [42] [43] [44] The data from the current meta-analysis suggest that the impact of IL-28B appears to be similar in all of the patient subgroups analysed and was not greatly influenced by duration of therapy or other study characteristics, except in Caucasian mono-infected patients. Nonetheless, additional large prospective studies involving the full spectrum of HCV patients that are likely to be encountered in clinical practice, including patients of Hispanic ethnicity, are needed to provide more robust models for clinicians to use. The choice of which IL-28B SNP to use in testing varies by patient race. A recent retrospective database study demonstrated that while there is a high concordance between rs12979860 and rs8099917 in Asians, the rate of concordance is substantially lower in non-Asian populations. 13 Several of the Asian studies included in this meta-analysis confirmed this finding by genotyping patients at both SNPs. 26, 29, 30 In contrast, it appears that a larger proportion of patients are classified as the favourable IL-28B genotype when the rs8099917 SNP is utilised in Caucasian studies. 19, 20, 24 Therefore, use of the rs8099917 SNP in non-Asian populations may lead to misclassification of IL-28B genotype and reduce the ability to accurately predict SVR. The role of IL-28B genotyping also needs to be better defined in the era of DAAs, such as telaprevir and boceprevir. The DAAs in combination with pegIFN and ribavirin are associated with significantly higher SVR rates in genotype 1 patients compared with dual therapy. However, the role of IL-28B genotyping in DAA treated patients remains unclear as uniform testing for this parameter was not conducted in the phase 3 multicenter licensing trials. Nonetheless, IL-28B genotype has been shown to be a predictor of SVR in smaller subgroups of patients undergoing triple therapy with a DAA, PegIFN and ribavirin. 45, 46 However, triple therapy is also associated with greater costs and more side effects including rash and anaemia, and current regimens using DAAs may increase the risk of developing viral resistance. Furthermore, a recent analysis demonstrated that triple therapy is not cost-effective in subjects with an IL-28B CC genotype due to their excellent response to dual therapy. 47 Therefore, our pooled data of the strength of association between IL-28B genotype and SVR in different patient populations receiving only pegIFN and ribavirin may prove important to regulatory agencies, clinicians, patients and third party payers. Despite their increased potency, DAAs are not currently approved in many important subgroups including HCV patients with genotype 2/3 infection and all HIV coinfected patients. In HIV co-infected patients, there is a particular concern for drug-drug interactions between the available protease inhibitors and several of the commonly used antiretroviral agents. Therefore, IL-28B testing may play a particularly important role in HIV/HCV co-infected patients contemplating pegIFN and ribavirin therapy until additional DAAs are developed and tested. Recent data suggest that IL-28B genotyping in conjunction with baseline HCV viral load may help identify HIV co-infected patients who are likely to achieve SVR. 48, 49 A limitation of the current study includes our inability to directly compare the role of IL-28B genotyping to other host, viral and therapeutic factors in a multivariate manner. Therefore, additional studies that incorporate multiple pre-treatment predictors with genetic data in a large cohort of prospectively treated patients who are given the same treatment regimen are needed. Nonetheless, robust and consistent associations of IL-28B genotype and SVR were shown in all of the groups analysed (Figures 3& 4) . In addition, our results support recent reports of low concordance between the two major IL-28B SNPs in some Caucasian populations. 13 For this meta-analysis of a predictive genetic test, we had to create our own study quality assessment scale which has not been independently validated. Furthermore, studies of the IL-28B polymorphisms in the African-American population remain limited (Table 1) . Nonetheless, the current meta-analysis represents the largest pooling of IL-28B genotype data in peg-IFN and ribavirin treated patients to date. Lastly, all of the studies of HIV co-infected patients were from Spain, and whether the results will be generalisable to other HIV coinfected patients treated in other countries requires further study.
In conclusion, the current meta-analysis shows that the favourable IL-28B genotype is associated with a significantly higher SVR rate in HCV genotype 1 patients treated with pegIFN and ribavirin. Furthermore, this finding is consistent across different racial groups who have varying distributions of the IL-28B polymorphism as well as in Caucasian HCV patients with HIV co-infection. IL-28B genotype was also significantly associated with the likelihood of achieving RVR in a limited number of studies. Although further studies are needed to develop a more comprehensive predictive model of SVR, IL-28B genotyping will likely play an important role in guiding treatment decisions for HCV genotype 1 patients seeking pegIFN and ribavirin based therapy. 
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